The Application of Cell and Gene-Modified Cell Therapy in the Treatment of Osteopetrosis
- 14 May 2026
- journal article
- review article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 37 (13-14) , 566-578
Abstract
Bone tissue represents a dynamic tissue that undergoes continuous renewal and remodeling through the coupled actions of osteoblast-driven bone formation and osteoclast-mediated bone resorption. Proper coupling between these two processes is essential for maintaining bone homeostasis, whereas its disruption leads to skeletal pathology. Excessive osteoclast activity underlies disorders such as osteoporosis and Paget’s disease, while osteoclast deficiency, either quantitative or functional, results in osteopetrosis. Osteopetrosis comprises a group of genetically heterogeneous and clinically variable rare metabolic bone diseases characterized by increased bone mass. Clinically, osteopetrosis is commonly classified into severe autosomal recessive osteopetrosis (ARO), also known as infantile malignant osteopetrosis, intermediate ARO, milder autosomal dominant osteopetrosis, and X-linked recessive osteopetrosis. Effective treatment options for both severe and milder forms of osteopetrosis remain an unresolved clinical challenge. This review sheds light on the potential of cell-based and gene-modified cell therapies as emerging strategies for the treatment of osteopetrosis. Current cell-based therapy approaches increasingly focus on induced pluripotent stem cells, while recent advances in gene therapy enable the correction of causative genetic defects through viral vector-mediated gene transfer, CRISPR/Cas9-based genome editing, or RNA interference-mediated gene silencing. In addition, the therapeutic potentials of immunological approaches based on recombinant human interferon gamma-1b is discussed. Despite significant progress, sustained research efforts are still required to translate cell and gene-modified cell therapy into effective and personalized clinical treatments for osteopetrosis.Keywords
Funding Information
- Branch of SASA (Serbian Academy of Sciences and Arts) in Niš (?-42-26)
- Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja (451-03-34/2026-03/200113)
This publication has 102 references indexed in Scilit:
- Effect of Allele-Specific Clcn7G213R siRNA Delivered Via a Novel Nanocarrier on Bone Phenotypes in ADO2 Mice on 129S BackgroundCalcified Tissue International, 2024
- Open‐Label Pilot Study of Interferon Gamma–1b in Patients With Non‐Infantile OsteopetrosisJBMR Plus, 2022
- How we approach malignant infantile osteopetrosisPediatric Blood & Cancer, 2020
- Efficient generation of osteoclasts from human induced pluripotent stem cells and functional investigations of lethal CLCN7-related osteopetrosisJournal of Bone and Mineral Research, 2020
- Interferon Gamma-1b Does Not Increase Markers of Bone Resorption in Autosomal Dominant OsteopetrosisJournal of Bone and Mineral Research, 2019
- Osteogenic potential of in vitro osteo-induced adipose-derived mesenchymal stem cells combined with platelet-rich plasma in an ectopic modelInternational Orthopaedics, 2015
- Interferon Gamma, but not Calcitriol Improves the Osteopetrotic Phenotypes in ADO2 MiceJournal of Bone and Mineral Research, 2015
- Gene Targeting of Human Pluripotent Stem Cells by Homologous Recombination2014
- A tightly regulated and reversibly inducible siRNA expression system for conditional RNAi‐mediated gene silencing in mammalian cellsThe Journal of Gene Medicine, 2007
- Osteoclast diseasesMicroscopy Research and Technique, 2003